Here's What 3M's Big News Means to Investors

Source The Motley Fool

At a glance, it's understandable that 3M's (NYSE: MMM) recent investor day didn't produce a significant move in the stock price. The industrial conglomerate's three-year targets were solid enough but not sufficiently inspiring to encourage investors to significantly upgrade medium-term expectations.

However, based on the presentations, there's a strong case for 3M being able to deliver good returns in the coming years, with more to come over the long term. That's likely to suit many investors, and it's why the stock remains attractive to buy. Here's the lowdown.

Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »

3M's financial targets

The financial targets laid out by management at the event are shown in the table below. Prospects for earnings growth are clearly coming not from organic sales but from expectations for higher margins, with management aiming to hit a 25% operating margin by 2027.

Here's some quick math to make sense of what this table means for potential returns. If we pencil in the midpoint of 2025 guidance ($7.75) and assume 8% growth in 2026 and 2027 -- that's the midpoint of the 7% to 9% range usually defined as "high single digits" -- we get earnings per share of $9.04 in 2027. If we assume the stock trades at 20 times earnings, around the historical norm, it would reach $181 in 2027, resulting in a 6.4% annual return based on recent prices. Including a 2% dividend yield would mean an 8.4% yearly return.

That outcome would provide a solid enough return but not a particularly exciting one. That said, there is a pathway to a better return for investors.

3M Guidance

2024

2025 Est.

2026/2027 Est.

Organic sales growth

1.2%

2%-3%

"outperform macro"

Operating margin

21.4%

130 bp* to 190 bp expansion

~100bps annually

Earnings per share

$7.30

$7.60-$7.90

High-single-digit annual growth

Free cash flow

$4.9 billion

~100% conversion from net income

>100% conversion from net income

Data source: 3M presentations, *bp is basis points, where 100bp=1%

How 3M can generate super returns for investors

In a nutshell, the upside opportunity comes from the potential for 3M to realize CEO Bill Brown's aim of revitalizing its new product introductions (NPIs). Doing so will likely lead to a pick-up in sales growth and margin expansion over the long term. As such, by 2027, investors in 3M could be pricing in better earnings growth in the future.

NPIs tend to be differentiated products that command pricing power, and 3M can ramp up volume production as they gain in popularity, resulting in sales growth and margin expansion. Given the gestation period necessary to fundamentally change a research and development function, develop NPIs, and establish them in the market, it won't be an overnight process.

Research and development functions.

Image source: Getty Images.

Still, there's plenty of room for improvement at 3M, and investors have cause for optimism. For example, management disclosed that its five-year NPI sales was $7 billion in 2018, but that figure slumped to just $2.4 billion in 2024 due to a dearth of NPI.

The slump in NPIs meant 3M's New Product Vitality Index (NPVI) (representing the share of total company sales from NPI over the last five years) slumped to just 10% in 2024 (compared to figures of 33% a decade ago). Management plans to get its NPVI to about 20% in 2027 through focused investment and implementing process improvements that should reduce its time to market for NPI.

Why 3M can improve NPI

It was refreshing to hear chief technology officer John Banovetz openly outline why 3M's NPI had fallen behind in recent years. The good news is that all three reasons are likely to prove temporary.

  • 3M had cut back on local product development
  • 3M was focused on reengineering products in light of the removal of PFAS compounds in its products and the need to adjust to the supply chain crisis caused by the lockdowns
  • Management had overinvested time and money in the healthcare business, now spun off as Solventum

These are entirely plausible arguments and issues likely to have caused disruptions, and given management's commitment to reinvigorating research and development, working through the PFAS-induced changes, and the absence of the healthcare business, 3M has an opportunity to improve NPIs.

An investor at a desk.

Image source: Getty Images.

A stock to buy

If 3M can generate the operational improvements necessary to improve long-term margin and NPIs, the market could start pricing in improved long-term growth prospects. The back-of-the-envelope figure of a yearly total return of 8.4% calculated above has upside potential. That might suit many investors looking for a relatively safe way to invest in the industrial sector.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $295,759!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,128!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $525,108!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Continue »

*Stock Advisor returns as of March 3, 2025

Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends 3M. The Motley Fool recommends Solventum. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Ripple Co-Founder Tied To Untouched XRP Holdings Worth Billions—Crypto SleuthA blockchain investigator discovered a series of dormant XRP wallets linked to Ripple co-founder Chris Larsen, which had over 2.7 billion XRP. These holdings are worth around $7.18 billion. Some of
Author  NewsBTC
23 hours ago
A blockchain investigator discovered a series of dormant XRP wallets linked to Ripple co-founder Chris Larsen, which had over 2.7 billion XRP. These holdings are worth around $7.18 billion. Some of
placeholder
Gold price depreciates as US Dollar gains ground amid rising Treasury yieldsGold price (XAU/USD) halts its two-day winning streak on Wednesday as rising US Treasury yields pressured non-yielding assets.
Author  FXStreet
19 hours ago
Gold price (XAU/USD) halts its two-day winning streak on Wednesday as rising US Treasury yields pressured non-yielding assets.
placeholder
Bitcoin Cash Price Forecast: BCH rallies as transaction rate reaches a new all-time highBitcoin Cash (BCH) price is rallying more than 7%, trading around $342 on Wednesday after retesting its key support level the previous day.
Author  FXStreet
18 hours ago
Bitcoin Cash (BCH) price is rallying more than 7%, trading around $342 on Wednesday after retesting its key support level the previous day.
placeholder
Why AAVE is rallying even as Bitcoin, Ethereum, XRP lagAave (AAVE), the native token of the Aave lending protocol, is rallying on Wednesday as the crypto market recovers from Monday’s bloodbath.
Author  FXStreet
14 hours ago
Aave (AAVE), the native token of the Aave lending protocol, is rallying on Wednesday as the crypto market recovers from Monday’s bloodbath.
placeholder
Trump Tariffs a Lose-Lose Game, JPMorgan: Tactically Bearish on US StocksTradingKey - US President Donald Trump's tariff measures are continuously putting pressure on the US economy and the US stock market. J.P. Morgan has shifted its outlook on US stocks to a tactical bea
Author  TradingKey
14 hours ago
TradingKey - US President Donald Trump's tariff measures are continuously putting pressure on the US economy and the US stock market. J.P. Morgan has shifted its outlook on US stocks to a tactical bea
goTop
quote